Rapport Therapeutics Secures $21 Share Private Placement, Boosting Third Rock Venture Ownership to 6M+ Shares
Rapport Therapeutics’ recent private placement shows Third Rock’s confidence: over six million shares acquired at $21, signaling growth prospects amid market volatility.
3 minutes to read